Volume 13, Issue 2 (8-1999)                   Med J Islam Repub Iran 1999 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

FALLAH A. EFFICACY AND SAFE TY OF LAMOTRIGINE AS A DD-ON THE RAPY IN 132 CHILDREN AND ADULT IRANIAN PATIENTS WITH TREATMENT-RESISTANT EPILEPSY. Med J Islam Repub Iran 1999; 13 (2) :107-110
URL: http://mjiri.iums.ac.ir/article-1-951-en.html
From the Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran.
Abstract:   (4475 Views)
This study was initiated to evaluate the long-term safety, tolerability and efficacy of seizure control of lamotrigine (LTG) in children and adult patients with partial seizures (PS) with or without secondary generalized seizure. A total of 132 patients (age 5-41 years) with treatment-resistant epilepsy received LTG as addon therapy for up to four years. Overall, patients were treated with LTG for 27 -226 weeks. The global assessment of seizure control compared to the three-month period before starting LTG treatment indicated that seizure control was gradually maintained during long-term LTG treatment for up to four years. The medical history of 23 patients who had a significant decrease in the number of seizures with LTG treatment indicated a subjective improvement in behavior, alertness, and quality of life. All 132 patients who received LTG as add-on therapy had used 2- 4 anti-convulsive medications 2-7 years before entering this open continuation study. Patients had 7-45 seizures per month throughout the 3 months before entering this study. The overall decrease in the number of seizures was 58% after patients started receiving LTG. LTG was well tolerated. The majority of adverse effects were classified as being mild in intensity and only 5 patients (4%) were withdrawn from the study due to adverse effects (skin rash).
Full-Text [PDF 312 kb]   (1512 Downloads)    
Type of Study: Original Research | Subject: Pediatric

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.